These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22673382)

  • 1. [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
    Beck-Nielsen H
    Ugeskr Laeger; 2012 Jun; 174(23):1606-8. PubMed ID: 22673382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Van Gaal LF; Gutkin SW; Nauck MA
    Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.
    Katout M; Zhu H; Rutsky J; Shah P; Brook RD; Zhong J; Rajagopalan S
    Am J Hypertens; 2014 Jan; 27(1):130-9. PubMed ID: 24263424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
    Christensen M; Vilsbøll T; Knop FK
    Ugeskr Laeger; 2012 Aug; 174(34):1935; discussion 1935. PubMed ID: 23077741
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing outcomes for GLP-1 agonists.
    Freeman JS
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS15-20. PubMed ID: 21389295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B
    Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
    Mateos JL; Wajchenberg BL
    Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of albiglutide for the treatment of type 2 diabetes.
    Rendell MS
    Expert Opin Drug Saf; 2017 Sep; 16(9):1089-1097. PubMed ID: 28678550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
    Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
    Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
    Holst JJ; Seino Y
    Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
    [No Abstract]   [Full Text] [Related]  

  • 20. Psychological and quality of life changes in patients using GLP-1 analogues.
    Grant P; Lipscomb D; Quin J
    J Diabetes Complications; 2011; 25(4):244-6. PubMed ID: 21601480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.